Pembrolizumab plus Pemetrexed and Platinum in Nonsquamous Non–Small-Cell Lung Cancer (KEYNOTE-189)
Source: View publication →
The addition of pembrolizumab to pemetrexed and platinum-based chemotherapy significantly improves overall survival and progression-free survival in patients with previously untreated metastatic nonsquamous non-small cell lung cancer, regardless of PD-L1 expression.
Key Findings
Study Design
Study Limitations
Clinical Significance
This trial established the 'triplet' regimen of pembrolizumab, pemetrexed, and platinum-based chemotherapy as a standard-of-care, first-line treatment for metastatic nonsquamous non-small cell lung cancer lacking targetable EGFR or ALK mutations, effectively doubling the efficacy of traditional chemotherapy and setting a new benchmark for patient outcomes in the first-line setting.
Historical Context
Before KEYNOTE-189, platinum-based doublet chemotherapy was the standard of care for metastatic NSCLC without sensitizing driver mutations. Following promising Phase 2 data from KEYNOTE-021 (Cohort G), KEYNOTE-189 served as the pivotal Phase 3 confirmatory study that solidified the role of immune checkpoint inhibitors in the first-line therapeutic landscape, even for patients with low or negative PD-L1 expression.
Guided Discussion
High-yield insights from every perspective
What is the biological rationale for combining cytotoxic chemotherapy with pembrolizumab, and how does this synergistic approach overcome immune evasion in nonsquamous non-small-cell lung cancer (NSCLC)?
Key Response
Cytotoxic chemotherapy promotes 'immunogenic cell death,' which releases tumor-associated antigens and pro-inflammatory cytokines. This increases the visibility of the tumor to the immune system. When combined with pembrolizumab (a PD-1 inhibitor), which prevents the tumor from 'turning off' T-cells via the PD-1/PD-L1 checkpoint, the immune system is better primed and unleashed to mount a more effective anti-tumor response than either modality could achieve alone.
In a patient with metastatic nonsquamous NSCLC and a PD-L1 Tumor Proportion Score (TPS) of <1%, how should the findings of KEYNOTE-189 influence your first-line treatment recommendation compared to chemotherapy alone?
Key Response
KEYNOTE-189 demonstrated a significant survival benefit for the addition of pembrolizumab to pemetrexed-platinum chemotherapy across all PD-L1 expression levels. Specifically, even in the PD-L1-negative group (TPS <1%), the hazard ratio for death was 0.59. Therefore, the presence of pembrolizumab should be part of the first-line regimen regardless of low or negative PD-L1 expression, unless specific contraindications to immunotherapy exist.
When considering the OS benefit observed in KEYNOTE-189, how do you reconcile the choice between pembrolizumab monotherapy (per KEYNOTE-024) and the KEYNOTE-189 triplet for a patient with PD-L1 TPS ≥50%?
Key Response
While both are Category 1 options, the choice involves balancing tumor burden and patient fitness. The KEYNOTE-189 triplet generally offers higher objective response rates (47.6%) and may be preferred in patients with high tumor burden or symptomatic disease where a rapid response is prioritized. Conversely, monotherapy (KEYNOTE-024) might be preferred for patients who are less fit for intensive chemotherapy, as it spares them the toxicities of platinum-pemetrexed while still offering durable survival benefit.
How does the 'tail of the curve' observed in KEYNOTE-189 change the clinical dialogue regarding prognosis and long-term maintenance in metastatic lung cancer compared to the previous platinum-doublet era?
Key Response
Before KEYNOTE-189, metastatic NSCLC was viewed almost exclusively through a palliative lens with a predictable decline. The plateauing of the survival curve suggests that a subset of patients may achieve long-term, durable responses. This necessitates a shift in teaching toward managing immunotherapy-related adverse events (irAEs) over long durations and discussing the potential for a 'chronic disease' state with patients rather than just short-term survival extensions.
Scholarly Review
Critical appraisal through the lens of expert reviewers and guideline development
The KEYNOTE-189 trial allowed for a crossover rate of nearly 50% from the placebo-combination group to pembrolizumab monotherapy upon progression. From a statistical standpoint, how does this crossover affect the interpretation of the Hazard Ratio for Overall Survival (OS)?
Key Response
Crossover typically biases the results toward the null hypothesis (an HR of 1.0) because the control group eventually receives the active treatment. The fact that KEYNOTE-189 still achieved a highly significant OS Hazard Ratio (0.49) despite this crossover suggests an exceptionally strong treatment effect for early (first-line) versus delayed (second-line) administration of pembrolizumab.
A critical reviewer might point out that KEYNOTE-189 excluded patients with EGFR or ALK mutations. How does this exclusion impact the study's generalizability and its significance in the evolving landscape of precision oncology?
Key Response
Excluding EGFR/ALK-mutated patients was essential for internal validity because these populations have a distinct biology, often respond poorly to PD-1 inhibitors, and have established targeted therapies (TKIs). However, it means the study's results cannot be generalized to all 'nonsquamous' patients. A tough reviewer would ensure the manuscript clearly defines its 'driver-negative' population to avoid clinicians inappropriately using this triplet as first-line therapy for patients who should receive targeted TKIs.
Based on the OS and PFS data from KEYNOTE-189, how should current guidelines grade the recommendation for pembrolizumab-pemetrexed-platinum as a first-line therapy, and how does it compare to the ASCO/NCCN standing for PD-L1 TPS 1-49% patients?
Key Response
KEYNOTE-189 provides Level 1, Category 1 evidence. For patients with TPS 1-49%, the triplet regimen is now the preferred standard because pembrolizumab monotherapy has not shown as robust a benefit in this subgroup as it has in the ≥50% group (per KEYNOTE-042). Guidelines were updated to reflect this, moving the chemo-IO combination to a 'preferred' status over platinum-doublet alone, which was the previous standard of care.
Clinical Landscape
Noteworthy Related Trials
KEYNOTE-021G
Tested
Pembrolizumab plus carboplatin and pemetrexed
Population
Treatment-naive stage IIIB/IV nonsquamous NSCLC
Comparator
Carboplatin and pemetrexed
Endpoint
Progression-free survival
IMpower150
Tested
Atezolizumab plus carboplatin, paclitaxel, and bevacizumab
Population
Metastatic nonsquamous NSCLC
Comparator
Carboplatin plus paclitaxel and bevacizumab
Endpoint
Progression-free survival and overall survival
KEYNOTE-407
Tested
Pembrolizumab plus carboplatin and paclitaxel/nab-paclitaxel
Population
Treatment-naive metastatic squamous NSCLC
Comparator
Placebo plus carboplatin and paclitaxel/nab-paclitaxel
Endpoint
Overall survival and progression-free survival
Tailored to your role
Want this tailored to you?
Add your specialty or training stage to get role-specific takeaways and more questions.
Personalize this analysis